Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Talk:Yohimbine

From PsychonautWiki Archive
Revision as of 21:34, 8 June 2019 by >Tracer (Edit)
Jump to navigation Jump to search

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Summary sheet: Yohimbine

Template:SubstanceBox/Yohimbine

Yohimbine hydrochloride (also known as quebrachine) is a naturally-occurring stimulant substance of the tryptamine class derived from the bark of the African tree Pausinystalia johimbe. Yohimbine is the major active constituent of the bark, with the active ingredient being yohimbine hydrochloride. It is commonly used as a fat-burning compound or for to treatment of erectile dysfunction.

Yohimbine is a drug used in veterinary medicine to reverse the effects of xylazine in dogs and deer. It is used as a research reagent. In the US it is prescribed, but now rarely, for erectile dysfunction in men.

Chemistry

Yohimbine is an indole alkaloid molecule of the tryptamine chemical class.

Pharmacology

In low doses yohimbine will antagonize alpha2 adrenergic receptors, leading to increased blood flow to the genital area, where blocking the presynaptic alpha2 receptors will lead to an increase in both nitric oxide & noradrenaline release. Blocking alpha-2 adrenoceptors increases blood pressure, releases insulin, and decreases blood sugar levels.

Yohimbine also, however, interacts with alpha1 adrenergic receptors, albeit with lower affinity, therefore, at higher doses an α1 blockade can occur and overwhelm the effects of the α2 blockade, making it difficult to predict the response, (alpha1 antagonism reduces blood pressure and overall CNS stimulation) and it will also influence other receptors.

Yohimbine behaves as an antagonist at dopamine D2 and D3 receptors, serotonin 5-HT1B, 5-HT1D, 5-HT2A, and 5-HT2B receptors, and as a partial agonist at 5-HT1A.[1]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Cognitive effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

Dependence and abuse potential

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.


See also

References

  1. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/10611634
  2. Yohimbine and rauwolscine reduce food intake of genetically obese (obob) and lean mice. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/6145164
  3. Evidence for activation of both adrenergic and cholinergic nervous pathways by yohimbine, an alpha 2-adrenoceptor antagonist. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/7557820
  4. Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24237691
  5. Cognitive Enhancers for Anxiety Disorders (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114287/
  6. Differential effects of noradrenergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/9004342
  7. Stimulation of the noradrenergic system enhances and blockade reduces memory for emotional material in man. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/10576300